Cancer
Conditions
Interventions
Gemcitabine
Sponsors
South Egypt cancer Institute
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients with advanced pancreatic cancer in males or females with age of 18 years or older, with an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2, chemotherapy-naïve, and adequate hematologic, hepatic, and renal functions.
Exclusion criteria
Exclusion criteria: 1. Patient refuses to be enrolled in study. 2. Contraindication to gemcitabine 3. Concurrent anticancer or radiation therapy. ? Start of study therapy must be at 4 weeks after completion of previous anticancer therapy and 2 weeks from the date of last radiation. 4. Use of gemcitabine within the past 3 months with progression. 5. Any psychiatric illness/social situations that would limit compliance with study requirements. 6. Pregnant or nursing women. 7. Synchronous malignancies i.e associated other body cancers.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary end points were progression free survival (PFS), defined as the time from the start of treatment to disease progression or death from any cause, whichever came first, and safety through assessment toxicity profile based on CTCAE. | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary efficacy end points were overall survival (OS; defined as the time from the start of treatment to disease progression, death from any cause, or date of last follow up, whichever came first.), overall response rate (ORR; defined as sum of rates of complete response (CR) and partial response (PR) to chemotherapy), and disease control rate (DCR; defined as sum of rates of stable disease (SD), complete response, and partial response). | — |
Countries
Egypt
Contacts
Public ContactMona Sayed
Assisstent Prof of clinical Oncology Prof
Outcome results
None listed